167 related articles for article (PubMed ID: 37955661)
1. [Metastatic castration-resistant prostate cancer-emerging trends in therapy].
von Amsberg G; Todenhöfer T
Urologie; 2023 Dec; 62(12):1289-1294. PubMed ID: 37955661
[TBL] [Abstract][Full Text] [Related]
2. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
3. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
4. Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies.
Labriola MK; Atiq S; Hirshman N; Bitting RL
Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):301-309. PubMed ID: 33168966
[TBL] [Abstract][Full Text] [Related]
5. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer.
Siu MK; Chen WY; Tsai HY; Chen HY; Yin JJ; Chen CL; Tsai YC; Liu YN
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):172-178. PubMed ID: 28220803
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.
Li H; Wang Z; Tang K; Zhou H; Liu H; Yan L; Guan W; Chen K; Xu H; Ye Z
Eur Urol Focus; 2018 Jul; 4(4):529-539. PubMed ID: 28753843
[TBL] [Abstract][Full Text] [Related]
7. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
[TBL] [Abstract][Full Text] [Related]
8. AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways.
Tortorella E; Giantulli S; Sciarra A; Silvestri I
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768370
[TBL] [Abstract][Full Text] [Related]
9. Androgen pathway resistance in prostate cancer and therapeutic implications.
Maughan BL; Antonarakis ES
Expert Opin Pharmacother; 2015; 16(10):1521-37. PubMed ID: 26067250
[TBL] [Abstract][Full Text] [Related]
10. Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
Zorko NA; Ryan CJ
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):986-996. PubMed ID: 34035459
[TBL] [Abstract][Full Text] [Related]
11. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
12. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
13. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer.
Wu M; Zhang R; Zhang Z; Zhang N; Li C; Xie Y; Xia H; Huang F; Zhang R; Liu M; Li X; Cen S; Zhou J
Elife; 2023 Jan; 12():. PubMed ID: 36656639
[TBL] [Abstract][Full Text] [Related]
14. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence.
Coutinho I; Day TK; Tilley WD; Selth LA
Endocr Relat Cancer; 2016 Dec; 23(12):T179-T197. PubMed ID: 27799360
[TBL] [Abstract][Full Text] [Related]
15. Androgen Receptor and Beyond, Targeting Androgen Signaling in Castration-Resistant Prostate Cancer.
Reichert ZR; Hussain M
Cancer J; 2016; 22(5):326-329. PubMed ID: 27749325
[TBL] [Abstract][Full Text] [Related]
16. Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
Anantharaman A; Friedlander TW
Urol Oncol; 2016 Aug; 34(8):356-67. PubMed ID: 26706121
[TBL] [Abstract][Full Text] [Related]
17. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
Liu VWS; Yau WL; Tam CW; Yao KM; Shiu SYW
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28561752
[TBL] [Abstract][Full Text] [Related]
18. Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.
Ware KE; Garcia-Blanco MA; Armstrong AJ; Dehm SM
Endocr Relat Cancer; 2014 Aug; 21(4):T87-T103. PubMed ID: 24859991
[TBL] [Abstract][Full Text] [Related]
19. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
20. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer.
Zarrabi KK; Narayan V; Mille PJ; Zibelman MR; Miron B; Bashir B; Kelly WK
Ther Adv Urol; 2023; 15():17562872231182219. PubMed ID: 37359737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]